Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | NOS1 | P29475 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1976939 | 0.85 | KMT2A (0.57) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL27483401 | 0.82 | CES1 (0.70) | TSHRLMNAGAACES1CA1 | |
| Terephthalamide SCHEMBL27950892 | 0.80 | TSHR (1.00) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL260727 | 0.80 | TSHR (1.00) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL7520487 | 0.80 | TDP1 (0.65) | TSHRLMNAGAACES1CA1 | |
| Urea SCHEMBL27805729 | 0.79 | TSHR (0.74) | TSHRLMNAGAACES1CA1 | |
| 4-Nitroaniline SCHEMBL29244703 | 0.78 | ALDH1A1 (0.78) | TSHRLMNAGAACES1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11203029 | 0.78 | TSHR (0.96) | TSHRLMNAGAACES1CA1 | |
| SCHEMBL628983 | 0.78 | TSHR (0.67) | TSHRLMNAGAACES1CA1 | |
| Potassium Ion SCHEMBL10621944 | 0.78 | CA1 (0.63) | TSHRLMNAGAACES1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107056666-B | A kind of organogel compound of 4- nitrobenzenes thiocarbamide and preparation method thereof, gel and application | 信阳师范学院 | 2018-09-14 | — | — | CN | claimed |
| CN-107056666-A | A kind of organogel compound of 4 nitrobenzene thiocarbamide and preparation method thereof, gel and application | 信阳师范学院 | 2017-08-18 | — | — | CN | claimed |
| EP-1126833-A4 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-1126833-A2 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025768-A1 | OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF | TREGA BIOSCIENCES, INC. (US) | 2000-05-11 | — | — | WO | claimed |
| EP-0755250-A4 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS INC (US) | 2000-04-19 | — | — | EP | claimed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | claimed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | claimed |
| JP-6293746-A | — | — | None | — | — | JP | disclosed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-117567332-A | Method for simultaneously synthesizing thioether compounds and nitrile compounds | 石河子大学 | 2024-02-20 | — | — | CN | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| CN-116585297-A | Application of sulfonamide derivative | 云南大学附属医院 | 2023-08-15 | — | — | CN | disclosed |
| US-5614520-A | 2-arylthiazole derivatives and pharmaceutical composition thereof | TEIJIN LIMITED (JP) | 1997-03-25 | — | — | US | disclosed |
| EP-0755250-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| EP-0513379-B1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1996-09-11 | — | — | EP | disclosed |
| WO-1995028153-A1 | BENZAMIDE-CONTAINING PHARMACEUTICAL COMPOSITIONS | CENTAUR PHARMACEUTICALS, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
| JP-H06293746-A | PRODUCTION OF (ALKOXYCYANOPHENYL)THIAZOLE DERIVATIVE | TEIJIN LTD | 1994-10-21 | — | — | JP | disclosed |
| EP-0513379-A1 | 2-ARYLTHIAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | TSHR 3541/4885LMNA 2516/4885GAA 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.